Managing Your Treatment Resistant Schizophrenia (TRS) With Clozapine

If you or someone you know has been prescribed Clozaril® there can be a lot of new information to take in and understand. To help you gain a better all-round understanding, Viatris have created Clozaril® connect - a hub of knowledge and information to help you make the most of your treatment experience with Clozaril®.


UK-CLZ-2025-00051 December 2025

The active ingredient and instructions for use are the same for Clozaril® and Clozapine Mylan. Any mention of Clozaril® would also apply to Clozapine Mylan.

This website is owned and managed by Viatris. This website is intended for patients prescribed Clozaril.

We recommend that you read the full Clozaril 25 mg Patient Information Leaflet or the Clozaril 100 mg Patient Information Leaflet carefully before using Clozaril®. If you are a healthcare professional, please click here.

Clozaril is indicated in treatment-resistant schizophrenic patients and in schizophrenia patients who have severe, untreatable neurological adverse reactions to other antipsychotic agents, including atypical antipsychotics. Treatment resistance is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two different antipsychotic agents, including an atypical antipsychotic agent, prescribed for adequate duration.

Clozaril is also indicated in psychotic disorders occurring during the course of Parkinson's disease, in cases where standard treatment has failed.

© Copyright 2025 Viatris Inc. All rights reserved. Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781)

Reporting of side effects : If you get any side effects or have a device failure, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Please report side effects or device failures with any medicine or vaccine to the medicines regulator MHRA through the Yellow Card Scheme. It is easiest and quickest to report side effects and device failures online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, prepaid Yellow Cards for reporting are available by writing to FREEPOST YELLOW CARD (no other address details necessary), by emailing yellowcard@mhra.gov.uk, by telephoning the Commission on Human Medicines (CHM) free phone line: 0800-731-6789, or by downloading and printing a form from the Yellow Card section of the MHRA website.

You should also report any side effects to Viatris at email address: cpms@viatris.com.